Elanco Animal Health (NYSE:ELAN) Director Lawrence Erik Kurzius Buys 40,000 Shares of Stock

Elanco Animal Health Incorporated (NYSE:ELAN) Director Lawrence Erik Kurzius bought 40,000 shares of the company’s stock in a transaction that occurred on Thursday, August 20th. The stock was bought at an average price of $23.40 per share, for a total transaction of $936,000.00. Following the acquisition, the director directly owned 188,647 shares of the company’s stock, valued at $4,414,339.80. The trade was a 26.91% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Elanco Animal Health Price Performance

Shares of ELAN opened at $24.05 on Friday. The firm has a fifty day simple moving average of $24.56 and a two-hundred day simple moving average of $24.01. The firm has a market cap of $12.02 billion, a PE ratio of -58.66, a P/E/G ratio of 1.41 and a beta of 1.67. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58. Elanco Animal Health Incorporated has a 1-year low of $17.11 and a 1-year high of $27.98.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.07. The firm had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.31 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The company’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period last year, the business posted $0.26 EPS. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, equities analysts anticipate that Elanco Animal Health Incorporated will post 1.12 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. AXQ Capital LP purchased a new position in shares of Elanco Animal Health during the 2nd quarter valued at about $1,242,000. Nykredit A S purchased a new stake in Elanco Animal Health in the 2nd quarter worth approximately $356,000. B. Metzler seel. Sohn & Co. AG increased its holdings in Elanco Animal Health by 55.7% in the 2nd quarter. B. Metzler seel. Sohn & Co. AG now owns 100,736 shares of the company’s stock worth $2,479,000 after acquiring an additional 36,038 shares in the last quarter. Proficio Capital Partners LLC purchased a new stake in Elanco Animal Health in the 2nd quarter worth approximately $260,000. Finally, Alyeska Investment Group L.P. bought a new stake in Elanco Animal Health during the 2nd quarter worth approximately $36,875,000. Institutional investors own 97.48% of the company’s stock.

Analysts Set New Price Targets

ELAN has been the subject of several research reports. UBS Group upped their price target on shares of Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Wall Street Zen lowered shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 24th. Citigroup boosted their target price on shares of Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. JPMorgan Chase & Co. upped their target price on shares of Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Finally, Piper Sandler reiterated an “overweight” rating on shares of Elanco Animal Health in a research report on Monday, June 29th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $29.09.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.